 鲜花( 85)  鸡蛋( 2)
|

楼主 |
发表于 2015-2-28 21:48
|
显示全部楼层
Stock soars after Cold-fX wins crucial approval$ n: V3 h0 i; g) `
: N, H& l) n4 _
EDMONTON - CV Technologies Inc. shares rose nearly 60 per cent Thursday after Health Canada approved the claims at the core of the company's marketing of its cold and flu drug Cold-fX.# z1 ^6 K4 [ _" d" D* `( T% p8 W
0 {# V7 s4 L& E- v4 QBY THE EDMONTON JOURNAL FEBRUARY 16, 2007! o& B* i" R* |3 t" I3 n% D
' ^, `' t7 i! l , L4 D& E U# Q6 e4 t' c9 `
EDMONTON - CV Technologies Inc. SHARES rose nearly 60 per cent Thursday after Health Canada approved the claims at the core of the company's marketing of its cold and flu drug Cold-fX.+ B, e: ]( J- V/ E2 C: O
1 C5 A0 D( f1 d3 R/ C3 v* R5 RThe agency said CV Technologies can continue to market Cold-fX as helping "to reduce the frequency, severity and duration of cold and flu symptoms by boosting the IMMUNE SYSTEM."
7 O0 s- i4 \8 a: m+ S1 m$ M: D7 m( h7 z9 J. X
The APPROVAL follows a review of seven clinical trials and more than 10 years of research about the product.
$ O; X3 ?. G. D6 S8 R8 I% a# H# X2 j
It should create even more confidence among consumers and medical professionals that the product works, CEO Jacqueline Shan said Thursday.& P7 l8 H/ u1 X6 k9 k, [7 k4 D* k, S
9 U P+ u; ^/ W; N- g2 u
It certainly instilled confidence in the market, as shares closed at $2.90 on THE TORONTO STOCK EXCHANGE, up $1.08 on a volume of 4.6 million.
9 W8 L2 H5 k: T3 F/ S! Y7 G( _' D0 [1 \. b/ ~
"As a scientist, it's one of the highlights of my CAREER," Shan said.
k& |/ [* F6 @6 W/ c6 P0 u9 N( Q; i7 l @6 ^3 e
"This approval is a breakthrough in realizing our vision of being a global leader in developing products for disease prevention."3 P" c1 h8 F V9 x, f f
; r" x$ H+ t1 D. H; q7 J6 u# W- S
It's Cold-fX's strongest medical recognition to date, said Shan. It means the company can advertise the HEALTH BENEFITS more effectively to consumers and health professionals, she said.' B6 m6 i! b/ O% F. L
@" [! c) ~+ z) j' S. I1 N
Ginseng-based Cold-fX is already the top-selling cold and flu treatment in Canada, but Shan said there is plenty of room for more growth.
5 t; ]0 v0 K, q# C% u K
, z, ~" ^4 A3 Y+ g; w; I% D; hThe approval will also help raise the product's PROFILE in the lucrative U.S. market, which Cold-fX entered in October. The move came with a new marketing push, using former Oilers superstar Mark Messier as its spokesman.4 J0 U) u& W) T) O
- ] I: p9 F# Y% v% u( ]6 J, Z4 B% [; V
http://www.canada.com/story.html ... 9-be80-f40f1426f662 |
|